The estimated Net Worth of Joanne Wendy Kim is at least $126 Tausend dollars as of 7 December 2021. Ms Kim owns over 2,000 units of BioVie stock worth over $5,780 and over the last 4 years she sold BIVI stock worth over $0. In addition, she makes $120,625 as CFO & Corp. Sec. at BioVie.
Ms has made over 1 trades of the BioVie stock since 2021, according to the Form 4 filled with the SEC. Most recently she bought 2,000 units of BIVI stock worth $10,800 on 7 December 2021.
The largest trade she's ever made was buying 2,000 units of BioVie stock on 7 December 2021 worth over $10,800. On average, Ms trades about 250 units every 0 days since 2020. As of 7 December 2021 she still owns at least 2,000 units of BioVie stock.
You can see the complete history of Ms Kim stock trades at the bottom of the page.
Joanne Wendy Kim CPA is the CFO & Corp. Sec. at BioVie.
As the CFO & Corp. Sec. of BioVie, the total compensation of Ms CPA at BioVie is $120,625. There are 1 executives at BioVie getting paid more, with Jonathan M. Adams M.B.A., MBA having the highest compensation of $267,199.
Ms CPA is 66, she's been the CFO & Corp. Sec. of BioVie since . There are 3 older and 7 younger executives at BioVie. The oldest executive at BioVie Inc. is Steven Gorlin, 82, who is the Director.
Joanne's mailing address filed with the SEC is C/O BIOVIE INC., 680 W NYE LANE STE 201, CARSON CITY, NV, 89703.
Over the last 9 years, insiders at BioVie have traded over $352,740 worth of BioVie stock and bought 67,100 units worth $464,015 . The most active insiders traders include Terren S Peizer, Steve Gorlin und Richard J Berman. On average, BioVie executives and independent directors trade stock every 122 days with the average trade being worth of $301,811. The most recent stock trade was executed by Cuong V Do on 4 March 2024, trading 10,000 units of BIVI stock currently worth $28,900.
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Santa Monica, California.
BioVie executives and other stock owners filed with the SEC include: